ESMO 2022 | CD8 T-cell receptor signatures prediciting clinical outcomes

Benjamin Fairfax, BM BCh, MRCP, PhD, University of Oxford, Oxford, UK, touches on the use of CD8 T-cell peripheral repertoire to predict outcomes to immune checkpoint inhibitors. Dr Fairfax highlights the use of peripheral blood which allows for dynamic monitoring of tumor development and response to therapy and may be vital in patients where tumor biopsy is difficult. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.